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a b s t r a c t
The majority of known major histocompatibility complex class I (MHCI)-associated tumor-derived pep-
tide antigens do not contain an optimal motif for MHCI binding. As a result, anchor residue-modified
‘heteroclitic’ peptides have been widely used in therapeutic cancer vaccination trials in order to enhance
immune responsiveness. In general, the improved stability of these heteroclitic complexes has been
inferred from their improved immunogenicity but has not been formally assessed. Here, we investigated
the binding of 4 HLA A*0201-restricted tumor-derived peptides and their commonly used heteroclitic
variants. We utilized a cell surface binding assay and a novel robust method for testing the durability
of soluble recombinant pMHCI in real time by surface plasmon resonance. Surprisingly, we show thatpMHC)
eteroclitic anchor residue-modified
eptide
MHC stability
-cells
ancer vaccines
heteroclitic peptides designed with optimal MHC binding motifs do not always form pMHCs that are
substantially more stable than their wildtype progenitors. These findings, combined with our recent dis-
covery that TCRs can distinguish between wildtype peptides and those altered at a primary buried MHC
anchor residue, suggest that altered TCR binding may account for a large part of the increased immune
response that can be generated by anchor residue-modified ligands. Our results further highlight the fact
that heteroclitic peptide-based immune interventions require careful evaluation to ensure that wildtype
ntainantigen specificity is mai
. Introduction
The T-cell receptor (TCR) governs T-cell mediated immunity
hrough the recognition of short peptide fragments bound tomajor
istocompatibility complexes (pMHCs) that are expressed on the
urface of almost all nucleated cell types. Formation of stable pMHC
lass I (pMHCI) that can be transported to the cell surface for exam-
nation by the TCR depends on the binding affinity between the
eptide and MHC. Peptides bind to MHC via interactions between
ndividual residuesandbindingpockets inagrooveon theMHCsur-
ace (Bjorkman et al., 1987; Guo et al., 1993). The most favorable
esidues at primary MHC anchor positions for the most common
aucasian human leukocyte antigen (HLA), HLA A*0201, have been
etermined by elution and sequencing of self-peptides bound to
LA A*0201 at the cell surface (Falk et al., 1991). The current pool
Abbreviations: pMHC, peptide–major histocompatibility complex; MFI, mean
uorescence intensity; FACS, fluorescent activated cell sorting; SPR, surfaceplasmon
esonance; TCR, T-cell receptor.
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of HLA A*0201-restricted tumor epitopes that have been identified
often contain sub-optimal primary HLA A*0201 anchor residues
and are not thought to form optimally stable pMHCIs. As a result,
a number of tumor specific ‘heteroclitic’ peptides, with modified
optimal anchor residues, have been developed that theoretically
improve the stability of tumor epitopes (Chen et al., 2000, 2005;
Keogh et al., 2001; Parker et al., 1994; Parkhurst et al., 1996; Reche
et al., 2004; Rosenberg et al., 2004; Terasawa et al., 2002). These
peptides have beendesigned by introducing ‘optimal’MHCanchor-
residues at peptide position 2 and the peptide C-terminus based
on: (i) peptide–MHC binding algorithms (Keogh et al., 2001) and
(ii) intelligent design (Chen et al., 2000; Parkhurst et al., 1996).
However, in most cases, the improved stability of these modi-
fied pMHCIs has been indirectly inferred due to the heightened
T-cell immunogenicity of these molecules. Thus, the improved
peptide–MHC affinity of these heteroclitic complexes has not been
directly assessed. Here we have developed a surface plasmon res-
onance (SPR) pMHC stability assay that detects changes in mass at
the surface of a gold plated sensor chip. This technology enables
the determination of pMHCI half-life by detecting protein density
at the sensor chip surface in real time. We have used this assay
and a more commonly used cell surface binding assay to compare
the stability of four MHCIs in complex with naturally expressed
tumor epitopes in parallel with their anchor residue-modified het-
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Table 1
Stability of wild-type, versus anchor residue-modified, peptide-MHCIs.
Peptide 1LogEC50 (M) 2Koff (s−1) 3Half-life (h)
KIFGSLAFL −3.885 9.5×106 20.1
KLFGSLAFV −3.389 1.5×105 12.8
SLLMWITQC −3.532 2.2×105 8.9
SLLMWITQL −4.365 1.9×105 10.1
VISNDVCAQV −4.301 1.1×105 16.9
VLSNDVCAQV −4.622 1.07×105 17.8
YLEPGPVA −3.587 3.3×105 5.8
YLEPGPVV −4.588 2.3×105 8.5
1LogEC50 (M) for the T2-binding assays were generated using multiple concen-
trations (100M, 50M, 10M and 1M) for each peptide to calculate the halfK.M. Miles et al. / Molecular
roclitic variants. We show that: (i) pMHCI stability data from our
iophysical assay are consistent with data independently gener-
ted from a cell-based assay that utilizes transport associated with
ntigen processing (TAP) deficient T2 cells (Henderson et al., 1992),
ii) altering a peptide in an attempt to improve MHC binding does
ot always correlate with an increase in stability over the wild-
ype progenitors, and (iii) commonly used peptide–MHC binding
lgorithms cannot always predict pMHC stability based on anchor
esidue-modifications.
. Materials and methods
.1. Generation of expression plasmids
The HLA A*0201  chain, tagged with a biotinylation sequence,
nd 2m were inserted into separate pGMT7 expression plasmids
nder the control of the T7 promoter as previously reported (Cole
t al., 2009) and the sequences were confirmed by automated DNA
equencing (Lark Technologies, Essex, UK).
.2. Peptides
Lyophilized peptideswere purchased fromProImmune (Oxford,
K). The peptides used in this study comprised: EBNA-1407–415
HPVGEADYF), influenza M158–66 (GILGFVFTL), NY-ESO-1157–165
SLLMWITQC, SLLMWITQL) (Chen et al., 2000), gp100280–288
YLEPGPVA, YLEPGPVV) (Parkhurst et al., 1996), HER-1/neu369–377
KIFGSLAFL, KLFGSLAFV) (Keogh et al., 2001), PSA178–187 (VISNDV-
AQV, VLSNDVCAQV) (Terasawa et al., 2002).
.3. Cell line
The mutant LCL×T-lymphoblastoid hybrid cell line,
74×CEM.T2 (referred to as T2 cells) is a mutant antigen-
resentation cell line (Henderson et al., 1992). These cells express
table human leukocyte antigen (HLA) class I molecules on their
urface in the presence of exogenous peptides. Cells were main-
ained in Gibco RPMI 1640 (Invitrogen, Carlsbad, CA, USA) and
upplemented with 10% heat inactivated foetal calf serum (FCS)
Invitrogen), 2mM l-glutamine (Invitrogen), penicillin 50Units/ml
Invitrogen) and streptomycin 50g/ml (Invitrogen).
.4. T2-binding assay
The T2-binding assay was performed as previously described
Bell et al., 2009). Briefly, T2 cells were washed in AIM-V media
Invitrogen), and concentrated to 106 cells/ml. The peptides were
repared in AIM-Vmedia and serially diluted providing concentra-
ions of 200M, 100M, 20M and 2M. The cells were mixed
:1 with each peptide dilution to give a final volume of 200L and
nal peptide concentrations of 100M, 50M, 10Mand 1M. A
LA A*0201 binding peptide, GILGFVFTL, and a non-HLA A*0201-
estricted peptide, HPVGEADYF (HLA-B*3501), were included as
ositive and negative controls respectively. The assay was sub-
ected to 10min incubation at 37 ◦C 5% CO2 before incubation at
oom temperature overnight. Cells were then incubated for 2h
t 37 ◦C and stained with mouse anti-human HLA A*0201:RPE
Serotec, Oxford, UK). The cells were washed twice with PBS and
nalyzed using a BD FACS Canto II (BDBiosciences Immunocytome-
ry Systems, San Jose, CA, USA), collecting 30,000 events in gate P1.
verage MFI of the HLA A*0201:RPE antibody staining was used to
easure the strength of binding in the T2 cell peptide–MHCI based
ssay. TheMFI reading fromtheFACSDiva softwarewasanalyzed in
raphPadPrism using a log (agonist) vs. response non-linear curve
o generate the logEC50 results.maximal response for each peptide–MHC interaction. The SPR biophysical stability
data were analyzed by using Langmuir dissociation analysis2 which was then con-
verted to half-life in hours3.
Heteroclitic modifications are shown in bold and underlined.
2.5. pMHCI refolding and biotinylation
pMHCI was refolded and biotinylated as previously reported
(Cole et al., 2007).
2.6. Real time SPR pMHC stability assay
The binding analysis was performed using a BIAcore 3000TM
(GE Healthcare, UK) equipped with a CM5 sensor chip as previ-
ously reported (Cole et al., 2008). For SPR-based pMHCI stability
assays,∼500RUsof biotinylatedpMHCIwere immobilized to strep-
tavidin,whichwas chemically linked to the chip surface. Aflowrate
of 10l/min was established for 15,000 s. The biophysical results
were analyzed by using Langmuir dissociation analysis which was
then converted to half-life in seconds. The biophysical binding
data from the BIAcore 3000TM was analyzed in the BIAevaluation
softwareTM (GE Healthcare).
3. Results
3.1. Analysis of pMHC stability using TAP deficient T2 cells
The binding of 4 different HLA A*0201-restricted tumor-
associated peptides was compared to their commonly used
heteroclitic variants using a cell surface pMHCI stabilization assay.
This assay made use of T2 cells that are deficient in the transporter
associatedwithantigenprocessing (TAP)and that therefore lack the
ability to transport peptide fragments into the endoplasmic retic-
ulum to form stable peptide–HLA A*0201 complexes (Henderson
et al., 1992). As a result, peptide–HLA A*0201 molecules expressed
on the cell surface of T2 cells are generally of low stability. Incuba-
tion of T2 cells with exogenous peptide that binds to HLA A*0201
stabilizes the molecule so that surface pMHC expression levels can
be quantitatively assessed (Bell et al., 2009). No peptide and the
HLA B*3501-restricted EBNA-1407–415 (HPVGEADYF) peptide were
usedasnegative controls forbinding, and theHLAA*0201 restricted
influenzaM158–66 (GILGFVFTL) peptide was used as a positive con-
trol for binding. Flow cytometric based analysis, using anti-human
HLA A*0201:RPE antibody, revealed that the wildtype antigen,
HLA A*0201-KIFGSLAFL, (logEC50 of −3.885M), was more stable
than the heteroclitic variant HLA A*0201-KLFGSLAFV (logEC50 of
−3.389M) that was designed to improve MHC binding (Fig. 1,
Table 1). However, thewildtypepMHCIs, HLAA*0201-SLLMWITQC,
HLA A*0201-YLEPGPVA and HLA A*0201-VISNDVCAQV were less
stable than their heteroclitic counterparts (Fig. 1, Table 1), albeit by
a relatively small degree. These data show that: (i) some hetero-
clitic peptides do not formmore stable pMHCIs than their wildtype
progenitors; and (ii) the difference in the stability between some
heteroclitic vs. natural pMHCIs, particularly VISNDVCAQV and
730 K.M. Miles et al. / Molecular Immunology 48 (2011) 728–732
Fig. 1. FACS analysis of pMHCI binding using TAP deficient T2 cells. We used TAP
deficient T2 cells, which lack the ability to transport peptide fragments to the endo-
plasmic reticulum to form stable pMHCI, to analyze the stability of the natural
and heteroclitic pMHCIs using FACS analysis. No peptide, and the HLA-B*3501-
restricted EBNA-1407–415 (HPVGEADYF) peptide were used as negative controls of
binding, and the HLA A*0201-restricted influenzaM158–66 (GILGFVFTL) peptide was
used as a positive control of binding. The mean fluorescence intensity (MFI) of cell
surface pMHCI staining with an anti-human HLA A2:RPE antibody revealed that
the natural tumor antigen, KIFGSLAFL, was more stable than the heteroclitic vari-
ant, KLFGSLAFV, whereas the natural tumor peptides SLLMWITQC, YLEPGPVA and
VISNDVCAQV were less stable than their heteroclitic counterparts: SLLMWITQL,
YLEPGPVV andVLSNDVCAQV.Data at a peptide concentration of 100Mare shown.
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Fig. 2. Real timeSPRpMHCstability assay.We immobilized eachwildtype andhete-
roclitic pMHCI pair to the surface of a CM5 chip using streptavidin-biotin coupling to
assess the half-life of each complex in real time. In a similar trend to the T2-binding
assay, we observed that; (A) the natural tumor antigen, HLA A*0201-KIFGSLAFL, had
a longer half-life compared to the heteroclitic variant, (A) HLA A*0201-KLFGSLAFV,
whereas the natural tumor antigens (B) HLA A*0201-SLLMWITQC, (C) HLA A*0201-
VISNDVCAQV and (D) HLA A*0201-YLEPGPVA had faster off-rates compared tohe binding assay was performed at a range of peptide concentrations (100M,
0M, 10M and 1M). LogEC50s (M) for this range are shown in Table 1. The
ean standard deviation, representing 4 separate experiments, is shown as error
ars.
LSNDVCAQV, could be very small. These unexpected findings
nderscored the need to develop a different technique to verify
he observations of the T2-binding assay.
.2. Real time SPR pMHC stability assay
One limitation of the T2-binding assay is its ability to reliably
easure ligands with weak-to-medium affinities. To overcome
his, we developed a highly sensitive biophysical assay to re-
nvestigate the pMHCI stability of the wildtype and heteroclitic
eptide cohort. The association of a peptide within the MHCI bind-
ng groove is required in order for the formation of a stable pMHCI
olecule. Peptides that bindweakly toMHCI, usually because they
onot containoptimal anchor residues, can result inunstable, short
ived complexes. Thus, by investigating different pMHCIs using
PR, we were able to directly measure and compare the effect of
eptide–MHCI binding on changes in mass at the surface of a CM5
ensor chip. In these experiments, we immobilized each wildtype
nd heteroclitic pMHCI pair to the surface of a CM5 chip using
treptavidin–biotin coupling and measured the dissociation rate
f each pMHCI in real time. A reduction in response units (RUs)
corresponding to a reduction in mass) over time was observed
Fig. 2). However, the loss of peptide from pMHCI complexes could
ot wholly account for this loss of mass due to the relatively small
ize of the peptide (∼1kDa). Instead, we reasoned that because
he MHCI heavy chain (1, 2 and 3 domains) was chemically
inked to the chip surface via a biotin–streptavidin interaction, the
ajority of this reduction was probably due to the dissociation
f 2 microglobulin from the MHCI heavy chain. This effect was
robably caused by destabilization of the pMHCI complex upontheir heteroclitic counterparts, (B) HLA A*0201-SLLMWITQL, (C) HLA A*0201-
VLSNDVCAQV and (D)HLAA*0201-YLEPGPVV. Data are representative of 3 separate
experiments.
loss of the antigenic peptide. Thus, this decay process represents
the stability of each pMHCI and infers the binding half-life of each
peptide. We observed the same general pattern of pMHCI stability
using SPR that was observed during the T2-binding assay (Fig. 1,
Table 1). Importantly, we were also able to determine the half-
life for each pMHCI in real time using our SPR pMHCI stability
assay. The wildtype antigen, HLA A*0201-KIFGSLAFL had a longer
half-life by 1.57 times compared to the heteroclitic HLA A*0201-
KLFGSLAFV variant (Fig. 2A, Table 1) even though the latter is
predicted to bind more strongly (Parker et al., 1994; Rammensee
et al., 1999; Reche et al., 2004) (Table 2). Conversely, the wild-
type HLA A*0201-SLLMWITQC, HLA A*0201-YLEPGPVA and HLA
A*0201-VISNDVCAQV had faster off-rates compared to their hete-
roclitic counterparts, HLAA*0201-SLLMWITQL (1.13 times slower),
HLA A*0201-YLEPGPVV (1.47 times slower) and HLA A*0201-
VLSNDVCAQV (1.10 times slower) (Fig. 2B–D, Table 1), confirming
that, in these instances,modification of the peptide anchor residues
K.M. Miles et al. / Molecular Immu
Table 2
Predicted stability of wild-type and anchor residue-modified pMHCIs using pMHC
binding algorithms.
Peptide aRANKPEP
binding score
bSYFPEITHI
binding score
cHLA BIND binding
score
KIFGSLAFL 89 26 235
KLFGSLAFV 99 30 11394
SLLMWITQC 62 18 42
SLLMWITQL 89 28 182
VISNDVCAQV 13 21 16
VLSNDVCAQV 16 23 118
YLEPGPVA −3.7 n/a n/a
YLEPGPVV 1.5 n/a n/a
Heteroclitic modifications are shown in bold and underlined.
a Prediction of peptide binding score to HLA A*0201 using RANKPEP (Reche et al.,
2004).
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iPredictionof peptidebinding score toHLAA*0201using SYFPEITHI (Rammensee
t al., 1999).
c Prediction of peptide binding score toHLAA*0201 usingHLA BIND (Parker et al.,
994).
mproved peptide–MHC affinity. However, most noticeably in the
ases of HLA A*0201-VISNDVCAQV and HLA A*0201-SLLMWITQC,
he difference in stability between the wildtype peptide and the
nchor improved peptide was minimal.
.3. Comparison of peptide–MHC binding algorithms vs.
xperimental pMHC stability assays
A number of pMHC algorithms have been developed in
rder to predict: (i) peptide epitopes for different MHCs and
ii) peptide–MHC binding, and/or stability (Parker et al., 1994;
ammensee et al., 1999; Reche et al., 2004). We used these algo-
ithms to determine the peptide binding score for thewildtype and
nchor residue-modified heteroclitic peptide cohort that we had
xperimentally tested (Table 2). In agreementwith the experimen-
al data, the peptide binding scores calculated using the RANKPEP
nd SYFPEITHI peptide–MHC binding algorithms for wildtype HLA
*0201-SLLMWITQC, HLA A*0201-YLEPGPVA and HLA A*0201-
ISNDVCAQV were only slightly lower than for their anchor
esidue-modified counterparts. The peptide binding scores calcu-
atedusing theHLA BINDalgorithmalso followed the same trendas
he experimental data, but predicted a more substantial difference
n pMHC binding for the wildtype HLA A*0201-SLLMWITQC, HLA
*0201-YLEPGPVA and HLA A*0201-VISNDVCAQV vs. the anchor
esidue-modified variants compared to RANKPEP and SYFPEITHI
Table 2). Interestingly, contrary to the experimental data, all of the
eptide–MHCbinding algorithms predicted scores for thewildtype
LA A*0201-KIFGSLAFL that were lower than for the heteroclitic
LA A*0201-KLFGSLAFV variant. This comparison underscores the
mportance of direct experimental determination of the effect of
nchor residue-modifications on pMHC stability.
. Discussion
Anumber of heteroclitic anchor residue-modifiedpeptides have
een designed in order to improve the interaction between the
ntigenic peptide andMHCI. These heteroclitic peptides have been
hown to generate enhanced immunogenicity compared to their
ildtype progenitors (Chen et al., 2000, 2005; Keogh et al., 2001;
arkhurst et al., 1996; Rosenberg et al., 2004; Terasawa et al., 2002).
owever, the proposed enhancement in stability of these pMHCs
as not been formally tested. This is partly because there are cur-
ently no standardized methods to robustly compare the binding
alf-life of low/medium affinity peptide–MHC interactions. Here,
e have designed and tested a real time biophysical assay for
nvestigating the degradation of soluble recombinant pMHCI innology 48 (2011) 728–732 731
comparison with a more widely used cell-based assay. We found
thatdatagenerated frombothassayswere largely inagreement, but
the SPR techniqueappeared superior indetecting subtledifferences
in low/medium affinity ligand dynamics. Additionally, compared
with strictly end-point analysis of the cell-based assay, the SPR
technique could measure detailed off-rate kinetics in real-time.
Importantly, across both assays, we observed that the difference
in stability between three-out-of-four of the heteroclitic pMHCIs
was enhanced compared to their wildtype progenitors, although to
an extremely small degree in the case of HLA A*0201-SLLMWITQL
and HLA A*0201-VLSNDVCAQV (Figs. 1 and 2, Table 1). We also
used a number of peptide–MHC binding algorithms (Parker et al.,
1994; Rammensee et al., 1999; Reche et al., 2004) to compare
the theoretical stability of the wildtype and heteroclitic pMHCIs
to our experimental findings. Although the peptide–MHC binding
algorithms were able to predict enhanced binding for some of the
anchor residue-modified heteroclitic peptides, theywere unable to
predict that the wildtype HLA A*0201-KIFGSLAFL was more stable
than the heteroclitic HLA A*0201-KLFGSLAFV variant. The increase
in binding in each casewas relativelyminor and it is difficult to rec-
oncile how a <1.6-fold difference in pMHCI stability can result in
an enhancement in immunogenicity of 10–100-fold (Keogh et al.,
2001; Lienard et al., 2004; Parkhurst et al., 1996; Rosenberg et al.,
2004, 1998; Speiser et al., 2002; Terasawaet al., 2002;Valmori et al.,
1998; Yu et al., 2004). Our recent examination of TCRs specific for
HLA A*0201-restricted peptides from Melan-A and preproinsulin
demonstrated thatTCRscandistinguishbetweenwildtypepeptides
and those that have been altered at a ‘buried’ MHC anchor residue
(Cole et al., 2010). These substantial differences in TCR/pMHCbind-
ing were confirmed by SPR and verified at the T-cell surface using
pMHC tetramers (Cole et al., 2010). Here, we demonstrate that
commonly used heteroclitic variant peptides designed to exhibit
improved MHC binding do not necessarily substantially improve
binding (Figs. 1 and 2). Nevertheless, it is well established that
these peptides are substantially more immunogenic and prime
significantly larger T-cell responses in vitro and in vivo. Unfortu-
nately, the widespread use of heteroclitic peptides has been of
limited clinical success (Rosenberg et al., 2004). In light of these
data and our new findings, it is likely that the theoretical improved
stability of heteroclitic pMHCIs (Table 2) is not thedominantunder-
lying mechanism that governs the enhanced immunogenicity of
these peptides. Since natural tumor epitopes are usually generated
from self-molecules, highly reactive tumor specific T-cells for these
structures are likely to be deleted in the thymus. However, because
heteroclitic variants are slightly different to wildtype sequences,
they may appear structurally ‘non-self’ to the immune system and
appear as immunogenic structures. Indeed, it is clear that small
changes in a peptide sequence can have very large effects on 3D
structure, repertoire formation and immunogenicity (Turner et al.,
2005; Valkenburg et al., 2010; Wieckowski et al., 2009). Likewise,
it is also clear that changes in the amino acid side chain in anMHC-
bound peptide can be transmitted along the peptide backbone and
result in subtle structural differences at distal peptide residues
(Reid et al., 1996; Theodossis et al., 2010). Thus, modification of
peptide anchor residues could have an unpredictable knock-on
conformational effect on the regions of the peptide that contact the
TCR. Our findings suggest that, the design of some anchor residue-
modified heteroclitic peptides may require careful revaluation in
order to ensure that the T-cells generated by the altered antigen
exhibit effective recognition of the natural tumor target.
In summary,weused a novel biophysical assay and a cell surface
binding assay to formally test the binding ofMHCI anchormodified
heteroclitic peptides that have been used in the clinic. Surprisingly,
we found that these pMHCIs were only moderately more stable
than their wildtype counterparts; indeed in one case the modified
pMHCI was less stable. The continued use of anchor modified pep-
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ides in the clinic is driven by their heightened immunogenicity.
ur results suggest that the increased responses to these peptides
annot be wholly accounted for by their enhancedMHC binding. In
ight of our recent study that documents that TCRs can distinguish
etween peptides that use a different buried anchor residue (Cole
t al., 2010),wesuggest that the increased immunogenicityofmany
nchormodified peptides ismost likely the result of these peptides
reating non-self-pMHCI structures. These findings therefore have
mportant implications for the use of altered peptide ligands (APL)
n vaccination strategies and suggest that any APL intended for use
n vaccination should be tested by in vitro priming to ensure that
esponding T-cells cross-react with the intended natural target.
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